← 홈

다발성 골수종

201개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 201개
AntibodyIndapta Therapeutics, INC.Phase 3

Isatuximab (Isatuximab)

NHL; Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#인기#항체+5
효능 ORR 67%임상시험 56상태 RECRUITING
ADCBiologicFortis Therapeutics, Inc.Phase 2

FOR46 (FOR46)

Multiple Myeloma; Multiple Myeloma in Relapse · Prostate Cancer Metastatic

#ProstateCancerMetastatic#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 51.5%임상시험 55상태 RECRUITING
CGTBiologicCarbiogene Therapeutics Co. Ltd.Phase 1

anti-BCMA CAR-T (anti-BCMA CAR-T)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#인기#세포유전치료+5
효능 ORR 97.1%임상시험 55상태 ACTIVE
AntibodyPfizerApproved

Elranatamab (Elranatamab)

Multiple Myeloma · FRα

#FR#Antibody#Approved#인기#항체+5
효능 ORR 61%임상시험 54상태 RECRUITING
AntibodyPfizerPhase 2

PF-06863135 (Elranatamab, Elranatamab (PF-06863135))

Multiple Myeloma · FRα

#FR#Antibody#Phase2#인기#항체+5
효능 ORR 61%임상시험 51상태 ACTIVE
ADCBiologicPfizerPhase 3

Iberdomide (Iberdomide)

Multiple Myeloma · FRα

#FR#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 92.9%임상시험 47상태 RECRUITING
AntibodyJack Khouri, MDPhase 2

Siltuximab (Siltuximab)

Multiple Myeloma; Cytokine Release Syndrome · Myelofibrosis

#Myelofibrosis#Antibody#Phase2#항체#면역항체+5
효능 ORR 46.7%임상시험 43상태 RECRUITING
CGTBiologicSung-Soo ParkPreclinical

IMiD treatment (IMiD treatment)

Multiple Myeloma, Relapsed; Multiple Myeloma (MM) · FRα

#FR#CGT#Preclinical#세포유전치료#CAR-T+5
효능 ORR 48.3%임상시험 39상태 RECRUITING
ADCBiologicJanssen Research & Development,…Phase 2

Nirogacestat (Nirogacestat)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 57%임상시험 32상태 RECRUITING
AntibodyBristol Myers SquibbPhase 2

nivolumab (Opdivo, Nivolumab plus Ipilimumab)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#항체#면역항체+5
효능 ORR 77.8%임상시험 32상태 RECRUITING
AntibodyRochederuxtecan, are effective i…Phase 2

trastuzumab (Herceptin, Trastuzumab plus Pertuzumab)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#항체#면역항체+5
효능 ORR 79.5%임상시험 32상태 RECRUITING
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab and Pertuzumab)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#항체#면역항체+5
효능 ORR 69.3%임상시험 31상태 RECRUITING
AntibodystaleGilead SciencesPhase 2

Magrolimab (Magrolimab)

Solid Tumor; Colorectal Cancer · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+4
효능 ORR 66.7%임상시험 30상태 DISCONTINUED
ADCBiologicstaleAmerican Society of Clinical On…Phase 2

Vemurafenib and Cobimetinib (Vemurafenib and Cobimetinib)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 65%임상시험 30상태 RECRUITING
AntibodystaleJanssenApproved

teclistamab OR talquetamab OR elranatamab OR linvoseltamab (teclistamab OR talquetamab OR elranatamab OR linvoseltamab)

Waldenstrom Macroglobulinaemia; Multiple Myeloma · Waldenstrom Macroglobulinaemia

#WaldenstromMacroglobulinaemia#Antibody#Approved#항체#면역항체+3
효능 ORR 50%임상시험 30상태 RECRUITING
ADCBiologicstaleGlaxoSmithKlinePhase 1

GSK2857916 (GSK2857916)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 100%임상시험 29상태 ACTIVE
ADCBiologicstaleDaiichi SankyoPhase 2

TDxD (Fam-Trastuzumab Deruxtecan-Nxki, Fam-Trastuzumab Deruxtecan-Nxki (TDxD))

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 71.7%임상시험 27상태 RECRUITING
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, Daratumumab and Recombinant Human Hyaluronidase)

Recurrent Multiple Myeloma; Refractory Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+4
효능 ORR 39.4%임상시험 25상태 RECRUITING
AntibodystaleJanssenPhase 1

daratumumab (Darzalex, Daratumumab/rHuPH20)

Multiple Myeloma; Non-Hodgkin Lymphoma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase1#항체#면역항체+3
효능 ORR 39.4%임상시험 24상태 ACTIVE
ADCBiologicstaleYOUNGIL KOHPhase 2

Mezigdomide (Mezigdomide)

Relapsed Refractory Multiple Myeloma (RRMM) · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 23상태 RECRUITING

2 / 11 페이지

← 이전다음 →